Tuesday, June 28, 2016 5:02:00 AM PDT | VentureDeal
Vista, California -- Rheumatology company Exagen Diagnostics has received $2.1 million in new venture capital debt investment, according to an SEC regulatory filing.
Exagen has developed technologies for the "diagnosis, prognosis and monitoring of autoimmune connective tissue disease." Investors in the financing were not disclosed, nor was how the company intends to use the funding proceeds. A total of six investors participated in the offering. CEO Ron Rocca has been with the firm since October 2011 and previously was general manager at Prometheus Labs.
Email Page | Print Page
Want unlimited access to the complete database with thousands of technology companies, VCs and transactions for only $25 per month?
Start your Free 14 Day Trial now – no obligation or credit card required.
